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Abstract
Background: Posttraumatic Stress Disorder (PTSD) is a commonly occurring mental illness. There are multiple
treatments for PTSD that have similar effectiveness, but these treatments differ substantially in other ways. It is
desirable to have well-informed patients involved in treatment choices. A patient decision aid (PtDA) is one method
to achieve this goal. This manuscript describes the rationale and development of a patient decision aid (PtDA)
designed for patients with PTSD.
Methods: We conducted an informational needs assessment of veterans (n = 19) to obtain their baseline
information needs prior to the development of the PtDA. We also conducted a literature review of effective PTSD
treatments, and we calculated respective effective sizes. A PtDA prototype was developed according to the
guidelines from the International Patient Decision Aid Standards. These standards guided our development of both
content and format for the PtDA. In accordance with the standards, we gathered feedback from patients (n = 20)
and providers (n = 7) to further refine the PtDA. The information obtained from patients and the literature review
was used to develop a decision aid for patients with PTSD.
Results: Patients with PTSD reported a strong preference to receive information about treatment options. They
expressed interest in also learning about PTSD symptoms. The patients preferred information presented in a
booklet format. From our literature review several treatments emerged as effective for PTSD: Cognitive Therapy,
Exposure Therapy, Eye Movement Desensitization Therapy, Selective Serotonin Reuptake Inhibitors, venlafaxine,
and risperidone.
Conclusion: It appears that the criteria set forth to develop decision aids can effectively be applied to PTSD. The
resultant PTSD patient decision aid is a booklet that describes the causes, symptoms, and treatments for PTSD.
Future work will examine the effects of use of the PTSD decision aid in clinical practice.
Trial registration: Clinicaltrials.gov identifier NCT00908440. Registered May 20, 2009.
Keywords: Shared decision making, Patient decision aid, Posttraumatic stress disorder, Patient-centered care
Background
Posttraumatic stress disorder (PTSD)
Posttraumatic stress disorder (PTSD) is a common psy-
chological disorder that can occur after exposure to a
traumatic event such as military combat, sexual/physical
assault, natural disasters, or vehicular crashes [1].
Symptoms of PTSD fall into four categories. These in-
clude intrusion symptoms (e.g., intrusive thoughts,
nightmares and flashbacks), avoidance (i.e., avoiding
thoughts, feelings, and people/places related to the
traumatic event), negative alterations in mood (inability
to remember, distorted cognitions, guilt), and arousal
symptoms (e.g., irritability, trouble sleeping, hyper-
arousal, and startle reflex) [1]. Individuals with PTSD
often experience financial, interpersonal, occupational,
legal, and/or housing problems [2]. PTSD can be a
severe and disabling condition.
* Correspondence: bradley.v.watts@dartmouth.edu
1VA National Center for Patient Safety, White River Junction, VT, USA
2White River Junction VA Medical Center, White River Junction, VT, USA
Full list of author information is available at the end of the article
© 2016 Watts et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Watts et al. BMC Psychiatry  (2016) 16:21 
DOI 10.1186/s12888-016-0724-x
PTSD prevalence
According to the National Comorbidity Survey–Replica-
tion, almost 7 % of adults in the United States (US) ex-
perience PTSD at some point in their lifetime [3]. The
presence of PTSD is even more common in populations
such as military combat veterans. According to the Na-
tional Vietnam Veterans Readjustment study, 30 % of
Vietnam veterans developed PTSD at some point follow-
ing the war [4]. The Rand Corporation’s Center for Mili-
tary Health Policy Research estimated that the current
prevalence of PTSD is 14 % among veterans of the re-
cent wars in Iraq and Afghanistan [5].
PTSD treatment
PTSD treatment in clinical practice has been informed by
several clinical practice guidelines that have been devel-
oped over the past decade [6–11]. Although the guidelines
differ slightly in their recommendations, there is consider-
able consensus. Several psychotherapies appear effective
(i.e., Cognitive Therapy, Exposure Therapy, and Eye Move-
ment Desensitization and Reprocessing Therapy). Cogni-
tive Therapies involve helping patients to restructure their
maladaptive thoughts or thoughts that maintain their
PTSD symptoms. The rationale is that such restructuring
will help patients replace thoughts associated with fear
with less distressing ones [12]. Exposure-based treatments
involve having patients repeatedly re-experience memories
of their traumatic event. The rationale is that this struc-
tured exposure to traumatic memories will help patients
gain control of their emotional responses to their trauma
and thus experience less fear [13]. Eye Movement
Desensitization and Reprocessing involves having patients
revisit their trauma memories while simultaneously per-
forming saccadic eye movements. The rationale underlying
Eye Movement Desensitization and Reprocessing Therapy
is that coupling eye movements with revisiting of trauma
memories will help patients gain control over their emo-
tional responses to their trauma [14].
There is also consensus among most practice guide-
lines regarding medication [6–11]. The guidelines gener-
ally agree that the selective serotonin reuptake inhibitors
(e.g., sertraline, fluoxetine, paroxetine) are an effective
treatment. This class of medications affects the neuro-
transmitter serotonin and has strong evidence from ran-
domized controlled trials supporting its use [15–18].
Similarly, selective norepinephrine reuptake inhibitors
such as venlafaxine have been recommended by practice
guidelines. This group of medications affects both sero-
tonin and norepinephrine and has been shown to be ef-
fective in randomized controlled trials [19].
Although there is considerable evidence that a variety
of treatments are effective for treating PTSD, there is no
single best treatment. However, few head to head studies
with adequate sample size have been conducted [20].
Shared decision making
Current concepts of quality advocate not only for the use of
effective treatments for a disorder, but also that the treat-
ments be patient-centered [21]. Patient-centered care is a
multidimensional construct that includes patient education
and incorporating patient preferences into clinical care
[22]. Shared decision making has been advocated as one
method of achieving patient- centered care [23]. The term
shared decision making refers to the communication that
takes place with patients who wish to be involved in their
health care decisions. Shared decision making is a method
that addresses one of the Institute of Medicine core aims
for improvement, patient-centered care [21]. Research sug-
gests that shared decision making is associated with positive
patient outcomes, such as increased knowledge, satisfaction
with treatment, and improvement in symptoms [23].
Patient decision aids
Shared decision making may include use of a patient de-
cision aid (PtDA), which is a condition-specific tool de-
signed to inform patients about treatment decisions.
PtDAs can take the form of booklets, DVDs, videos,
interactive computer programs, or websites [23]. PtDAs
are specifically designed to help patients understand and
choose between two or more relevant treatment options.
Effective PtDAs do this by providing patients with de-
tailed, high-quality, and balanced information about each
option’s possible benefits and potential risks. The PtDA
can help patients understand that the selection of a par-
ticular option is dependent on their informed prefer-
ences towards these benefits and risks.
The Cochrane Collaboration has systematically reviewed
over 115 randomized clinical trials of PtDAs for use in
screening, prevention, and medical-surgical care. The re-
view confirms that well-designed PtDAs help patients to
participate in making informed choices that are consistent
with their values [23]. Moreover, PtDAs were better than
treatment as usual when it came to increasing patients
knowledge and satisfaction with treatment [23].
Recent research has examined the use of PtDAs for
mental health disorders [24, 25]. In a study of patients
with schizophrenia a decision aid resulted in enhanced
patient knowledge of treatments [24]. Similarly a study
conducted in patients with major depressive disorder
found that patients’ use of PtDAs was associated with in-
creased involvement in decision-making and satisfaction
with mental health care.
In this paper, we describe the development of a PtDA for
PTSD. At the time of this study, no PtDA for PTSD was
available. PTSD is condition well-suited for a PtDA in that
there are several effective treatments [20, 26, 27]. PTSD
treatments do vary substantially in other ways. For ex-
ample, a patient with PTSD could reasonably choose psy-
chotherapy requiring a weekly visit with a therapist or
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medication therapy involving daily ingestion of a tablet at
home. We conducted a randomized trial comparing the
outcomes of patients who received the PtDa with patients
who recieved usual care. We found that the decision aid
led to greater knowledge about PTSD and less conflict
about their choice of tretament, as well as increased likeli-
hood of receiving evidence-based treatment and improved
PTSD outcomes. In this paper, we describe the develop-
ment of a PtDA for PTSD [28]. Below, we describe the
three step process that we used to develop the PtDA: 1) in-
formational needs assessment, 2) review of literature for
descriptions of PTSD and corresponding effective treat-
ments, and 3) prototype development.
Methods
General approach
This project was approved by the Dartmouth College
Committee for the Protection of Human Subjects and
registered on clinicaltrials.gov on May 20, 2009. Written
informed consent was obtained from all participants.
We were guided by the International Patient Decision
Aid Standards (IPDAS) collaboration criteria for both
content and development of the decision aid for PTSD
[23]. Briefly, IPDAS specifies that any PtDA should con-
tain the following: natural course of condition without
therapy, procedures for each treatment option, potential
benefits and disadvantages for each option, and prob-
abilities of benefits and side effects/harms. IPDAS cri-
teria for development of a decision aid are as follows:
based on current scientific evidence, conflicts disclosed,
and field tests with patients and practitioners to ensure
that the decision aid is acceptable and understood. The
development of this new decision aid involved three
steps that resulted in specifying the information content
and developing the prototype.
Step 1: Informational needs assessment
We recruited participants (n = 19) diagnosed with PTSD at
the White River Junction Veterans Affairs Medical Center
(VAMC). Participants could have a new or long standing
diagnosis of PTSD. Participants were not excluded due to
the presence or absence of any co-morbid medical or psy-
chiatric diagnosis. A research assistant conducted a 60-min
semi-structured interview with each participant. Partici-
pants were asked to report their opinions regarding (a)
information they wished to know about PTSD, (b) infor-
mation they felt they needed in order to make a thera-
peutic choice, and (c) their favored presentation format for
information. We continued to recruit participants with
PTSD to interview until consistent themes emerged among
the participating veterans’ responses (i.e., theoretical satur-
ation where no new themes emerge from participants and
concepts in a theory are well-developed) [29].
Step 2: Review of literature for description of PTSD and
its effective treatments
No definitive review of PTSD treatments was available.
Therefore, we conducted a comprehensive review and
analysis of effective treatments for PTSD. We searched
the relevant literature using PubMed, Medline, PILOTS,
Psycinfo, and the Cochrane Collaboration’s databases
from 1980 (the date of establishment of the Diagnostic
and Statistical Manual criteria for PTSD) until January 1,
2013 [31]. The search terms “post-traumatic stress disor-
ders,” “posttraumatic stress disorder,” “PTSD,” “combat
disorders,” and “stress disorders, post-traumatic” were
used [30]. The search results were limited to articles
indexed as clinical trials or those that included the terms
“treatment trial,” “randomized trial,” or “controlled trial”
in their title or abstract. In order to locate additional
sources, the authors systematically reviewed the refer-
ences cited in all included studies as well as previous re-
view articles or meta-analyses.
We considered only studies that (1) randomized par-
ticipants to one or more active treatments and to a con-
trol group; (2) involved only adult participants who all
met standard PTSD diagnostic criteria as set forth in the
third, revised third, or fourth editions of the Diagnostic
and Statistical Manual of Mental Disorders; and (3) in-
cluded pre-treatment and post-treatment measures of
PTSD symptoms [32–34]. Treatment trials of similar
types of therapy were pooled into treatment groupings.
Treatments were included in the decision aid only if: (1)
they differed statistically from the control group; and (2)
had been studied in 100 or more participants in all
pooled trials (including the total number in the treat-
ment and control groups).
We calculated an effect size, compared to control
group levels, for each type of treatment [34]. For manu-
scripts that provided data regarding response rates, we
also collected PTSD response rate. Treatment response
was defined as no longer meeting PTSD diagnosis [35–
37]. As most studies did not include the categorical data,
we imputed missing values for treatment response based
on the continuous outcome data. These response rates
were then used to develop the graphical displays used in
the PtDA.
For manuscripts that reported only a continuous
measure of outcome, we transformed the between
groups treatment effect size into a percentage response
rate that approximated PTSD treatment response. This
allowed us to derive a weighted, pooled, average re-
sponse rate for each particular treatment grouping.
We reviewed several of the leading references in the
field of PTSD in order to develop a description of PTSD
and description of the different PTSD symptoms and
treatments [7, 31]. The descriptions were modified as
needed to reflect a desired seventh grade reading level.
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Step 3: Prototype development
We elected to pursue development of a decision aid in
booklet format based on the feedback from the partici-
pants with PTSD, and we utilized an iterative design
process for the drafts of the booklets. For each draft that
was constructed, the booklet was reviewed by a commit-
tee that included experts in the field of patient decision
aids and experts in the field of PTSD. The committee
assessed whether the informational content met the
International Patient Decision Aid Standards, met the
informational needs of patients, and was consistent with
the published literature.
After six iterative reviews cycles, an initial version was
agreed upon. Patients with PTSD and providers who
treated such patients were asked to provide feedback
about the initial version. The focus of this field testing
was to obtain reports about the clarity of the PtDA
prototype. Participants (n = 20) with PTSD seeking treat-
ment from the White River Junction VAMC were re-
cruited and individually given the draft of the PtDA
decision aid. They were asked for feedback regarding
clarity of presentation, ability to hold attention, and
overall balance. These participants were different from
the initial group of veterans who participated in the
needs assessment. All participants were diagnosed with
PTSD and had been stable in treatment in the mental
health clinic for at least two years. The participants were
first allowed to review the draft version of the decision
aid, and then reviewed each page with research assistant
using a semi-structured questioning format.
In addition, psychiatrists and psychologists (n = 7)
working in the PTSD treatment clinic were shown the
decision aid and their feedback was sought. The pro-
viders were working in a specialized PTSD clinic. They
were well-versed in all of the evidence-based treatments
described in the PtDA. The provider group as a whole
had extensive experience with the described PTSD treat-
ments. Again, the feedback was collected through the
same review process by a research assistant who con-
ducted an interview guided by a semi-structured inter-
view tool.
Feedback from both participant and providers was in-
corporated into a second version of the PtDA. An inde-
pendent panel, who had not been involved in the
previous development or review steps, reviewed the final
version of the PtDA. Their feedback was collected and
incorporated into the final decision aid version.
Results and discussion
Step 1: Information needs assessment
Nineteen participants (16 men, 3 women) completed the
needs assessment interview. All participants were re-
cruited from the mental health clinic at the White River
Junction VAMC. Ages ranged from 28–66 years, with a
mean of 48 years. There was considerable variability in
the time they had been involved in treatment for PTSD
ranging from one month to 34 years, with a mean of
5.6 years.
When veterans were asked: “What do you want to
know about PTSD?” the majority (59 %, n = 11) wanted
to know about PTSD symptoms or its long-term effects
on health. For example, one veteran stated, “I don’t even
know what the doctor means by PTSD…which of my
problems are PTSD?” Another participant asked, “What
I want to know is what this stress thing is doing to my
heart.” Other issues that emerged with less frequency
were: knowing that PTSD is treatable (21 %, n = 4); real-
izing that “it’s not my fault” (11 %, n = 2); knowing that
PTSD is a mental illness (11 %, n = 2); and understand-
ing that PTSD is a disorder that affects many people
(11 %, n = 2).
Almost all participants (95 %, n = 18) also spontan-
eously reported that they wanted to know what treat-
ments were available for PTSD and wanted a description
of those treatments. One participant summed up many
others thoughts in saying, “Skip all the crap, just tell me
what works.” A majority (68 %, n = 13) also wanted to
know about specific treatment efficacy. “They keep say-
ing take such and such medication for PTSD, but how
well does it work.” Other themes that emerged with less
frequency included side effects (21 %, n = 4), availability
of treatments (10.5 %, n = 2), and coverage of treatments
by health insurance (10.5 %, n = 2).
When participants were asked: “How would you best
like the information presented to you,” most wanted in-
formation presented in a booklet (47 %, n = 9) or pre-
sented verbally by a counselor or doctor (31 %, n = 6). “I
want something that I can touch and hold,” as an ex-
ample was reported by one participant. A smaller per-
centage of participants (21 %, n = 4) wanted information
presented on the internet or via email. Other formats
that emerged were video (10.5 %, n = 2), and verbal com-
munication with veteran (5 %, n = 1). Please note three
partisipants equally preferred two formats thus the total
exceeds 19. There were no trends in the preferences
based on either patient age or era of military service.
Step 2: Review of literature for description of PTSD and
its effective treatments
One hundred and twelve manuscripts examining 137
different treatment trials met the inclusion criteria for
this review and were included in the analysis. Treat-
ments included individual psychotherapy, group psycho-
therapy, pharmacotherapy, and other novel treatments
for PTSD.
Several treatments showed a statistically significant
improvement in PTSD symptoms compared to the con-
trol condition. The treatments that were both more
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effective than control and studied in more than 100 par-
ticipants included psychotherapies (Cognitive Therapy,
Exposure Therapy, and Eye Movement Desensitization
and Reprocessing Therapy), and medications (selective
serotonin reuptake inhibitors, risperidone, and venlafax-
ine). As these treatments showed clear evidence of ef-
fectiveness, they were selected for presentation in the
draft PtDA.
A full description of the literature and meta-analysis
can be found in Watts et. al 2012 [20].
Step 3: Prototype development
The initial draft of the PtDA was twenty-one pages long.
The first page was a cover page; the second page listed
the goals of the PtDA, and then the PtDA itself con-
sisted of five sections that provided a description of
PTSD as well as information about its effective treat-
ments. Specifically, information was provided about indi-
vidual psychotherapy for PTSD, medications for PTSD,
and finally a summary about the different types of PTSD
treatment.
We received feedback on the draft from 20 partici-
pants currently receiving treatment at the White River
Junction VA. In addition, we received feedback from
four psychiatrists and three psychologists. None of the
participants or providers had been involved in the devel-
opment of the draft. Participant and provider feedback
was generally positive; respondents reported that the de-
cision aid was “easy to follow,” and “easy to read and
understand.” “The book seemed OK, it was pretty easy
and helpful,” report one participant. “Another reported,
“I think this would help a new veteran with PTSD pick a
therapy.” The primary concerns voiced by both partici-
pants and providers were that the graphics used to illus-
trate relative efficacy were difficult to understand (i.e.,
Fig. 1). “I didn’t get the smiley faces,” was a common
comment. In addition, multiple small changes were
recommended. These typically involved clarification and
simplification of the language.
Conclusions
We developed a PtDA designed for participants with PTSD
that reflected their informational needs and current know-
ledge about effective treatments (see Additional file 1 for
complete version of the decision aid). This decision aid
was developed using the established standards for the
development of a patient decision aid [28]. Early feedback
suggested that the PtDA was understandable to partici-
pants with PTSD and providers who treat PTSD. This sug-
gests that an acceptable decision aid can be developed for
participants with PTSD by using the standards in the field.
Based on the informational needs assessment, it was
clear that participants most wanted to know about
PTSD and the effective treatments for PTSD. This is
consistent with previous research that suggests that pa-
tients want to be more involved in their mental health
care (when compared to care for physical illnesses) [38].
The development of a PtDA for PTSD provides a first
step in the goal of providing more patient-centered care.
Some limitations should be noted. First, the treatments
described in this PtDA were limited to those that
emerged as effective from review of the published litera-
ture. While these treatments are likely to be effective for
PTSD, some participants may not have access to all the
treatments described. Second, as this PtDA was devel-
oped using feedback from participants receiving care at
a VA hospital, its applicability to other populations with
PTSD is unclear. It is possible that veterans with PTSD
have unique preference for information. Similarly, we re-
ceived considerable feedback from participants who had
already been treated for PTSD. It is possible that treat-
ment naive patients have different needs and prefer-
ences. Third, we sampled a small number of participants
and providers from a single PTSD clinic for feedback re-
garding the decision aid. It is possible this group of
Fig. 1 Visual depiction of treatment efficacy
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participants and providers may differ in important ways
from the general population of patients with PTSD and
providers who treat PTSD. In addition, we asked pro-
viders or participants to provide feedback about the
PtDA rather than use it. It remains to be seen whether
providers or patients will embrace such a tool. Likely
substantial barriers would be faced to get providers to
use the PTDA in typical practice. Future research should
focus on better understanding these barriers.
The presence of the decision aid does not guarantee
that care for patients with PTSD will be patient cen-
tered. We know little about how or if this tool will be
used; however, its availability provides a possible route
towards patient centered care which we think will be of
great interest to clinicians and researchers.
Although the development of the PtDA is a necessary
first step, many questions remain about the use and ef-
fectiveness of the PtDA for PTSD. Our randomized trial
found that the decision aid led to great knowledge and
better clinical outcomes [28]. Future research is needed
to further evaluate the effect on patients’ knowledge and
decision making. Similarly, we have only limited infor-
mation regarding what effect the PtDA for PTSD will
have on the processes of care (i.e. type of treatment re-
ceived) and PTSD symptom outcomes. We have little
understanding about how the PtDA could be incorpo-
rated into the care process for patients with PTSD. For
example, when is the best time to give the PtDA to the
patient, and whether it is important for the provider to
review the PtDA with the patient? Similarly we currently
have little knowledge about how patients would use the
PtDA. Will patients review the entire 21 page booklet,
or will they focus only on those pages describing treat-
ments they are most interested in having? If these im-
portant questions can be successfully addressed, there is
potential for the PTSD decision aid to facilitate patient
centered care for patients with PTSD.
Additional file
Additional file 1: Complete version of the decision aid. (PDF 176 kb)
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